These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9462684)

  • 41. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L; Moffat J; Martins H; Glickman B
    Cancer Res; 1997 Oct; 57(19):4393-407. PubMed ID: 9331103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha.
    Brandes LM; Lin ZP; Patierno SR; Kennedy KA
    Mol Pharmacol; 2001 Sep; 60(3):559-67. PubMed ID: 11502888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
    Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular response to etoposide treatment.
    Montecucco A; Biamonti G
    Cancer Lett; 2007 Jul; 252(1):9-18. PubMed ID: 17166655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
    Chen CL; Fuscoe JC; Liu Q; Pui CH; Mahmoud HH; Relling MV
    J Natl Cancer Inst; 1996 Dec; 88(24):1840-7. PubMed ID: 8961974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug resistance in the treatment of sarcomas.
    Colvin OM
    Semin Oncol; 1997 Oct; 24(5):580-91. PubMed ID: 9344325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
    Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
    Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the properties of human breast cancer cells: MCF-7 and MCF-7 cells selected for resistance to etoposide.
    Cory AH; Cory JG
    Adv Enzyme Regul; 2001; 41():177-88. PubMed ID: 11384744
    [No Abstract]   [Full Text] [Related]  

  • 53. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
    Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
    J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms.
    Alpsoy A; Yasa S; Gündüz U
    Biomed Pharmacother; 2014 Apr; 68(3):351-5. PubMed ID: 24529846
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ; Illand M; Kim YT; Paul J; Brown R
    Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polyamine acetylation and apoptosis.
    Lindsay GS; Wallace HM
    Biochem Soc Trans; 1996 May; 24(2):229S. PubMed ID: 8736887
    [No Abstract]   [Full Text] [Related]  

  • 57. Human basal cell carcinoma tumor-initiating cells are resistant to etoposide.
    Colmont CS; Ketah AB; Errington RJ; Reed SH; Udey MC; Patel GK
    J Invest Dermatol; 2014 Mar; 134(3):867-870. PubMed ID: 24025552
    [No Abstract]   [Full Text] [Related]  

  • 58. The clinical pharmacology of etoposide: an update.
    Joel S
    Cancer Treat Rev; 1996 May; 22(3):179-221. PubMed ID: 8841390
    [No Abstract]   [Full Text] [Related]  

  • 59. DNA repair: a double-edged sword.
    Wei Q; Frazier ML; Levin B
    J Natl Cancer Inst; 2000 Mar; 92(6):440-1. PubMed ID: 10716953
    [No Abstract]   [Full Text] [Related]  

  • 60. Antineoplastic drug resistance and DNA repair.
    Burt RK; Poirier MC; Link CJ; Bohr VA
    Ann Oncol; 1991 May; 2(5):325-34. PubMed ID: 1954176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.